U.S. markets open in 9 hours
  • S&P Futures

    3,368.75
    +16.75 (+0.50%)
     
  • Dow Futures

    27,844.00
    +180.00 (+0.65%)
     
  • Nasdaq Futures

    11,463.50
    +56.25 (+0.49%)
     
  • Russell 2000 Futures

    1,512.70
    +8.30 (+0.55%)
     
  • Crude Oil

    40.18
    -0.04 (-0.10%)
     
  • Gold

    1,897.80
    +2.30 (+0.12%)
     
  • Silver

    23.66
    +0.16 (+0.69%)
     
  • EUR/USD

    1.1745
    +0.0019 (+0.16%)
     
  • 10-Yr Bond

    0.6770
    -0.6450 (-100.00%)
     
  • Vix

    26.37
    -26.27 (-100.00%)
     
  • GBP/USD

    1.2937
    +0.0016 (+0.13%)
     
  • USD/JPY

    105.4460
    +0.0160 (+0.02%)
     
  • BTC-USD

    10,834.46
    +38.43 (+0.36%)
     
  • CMC Crypto 200

    233.17
    +11.78 (+5.32%)
     
  • FTSE 100

    5,866.10
    -31.40 (-0.53%)
     
  • Nikkei 225

    23,184.93
    -0.19 (-0.00%)
     

Elixxer Announces Amendment to Stock Option Plan and the Cancellation of Certain Options

Elixxer Ltd.

MONTRÉAL, Aug. 19, 2020 (GLOBE NEWSWIRE) -- Elixxer Ltd. (TSX-V: ELXR) (OTC-QB: ELIXF) (FRA: 2LQA) (“Elixxer” or (the “Company) announces that it has amended its stock option plan (the “Plan”) to increase the number of common shares that may be issued thereunder. The Plan is a fixed stock option plan, and the amendment increases the number of common shares reserved for issuance under the Plan from 83,331,796 to 112,101,606, being 20% of the Company’s issued and outstanding common shares as of the date hereof.

The amendment to the Plan is subject to the approval of (i) the TSX Venture Exchange and (ii) the Company’s shareholders which approval will be sought at the Company’s annual and special meeting of shareholders scheduled for September 22, 2020.

The Corporation also announces that it and certain insiders and consultants of Elixxer have agreed to cancel an aggregate of 16,800,000 stock options held by the optionees.  The cancelled options include (i) 7,500,000 options granted on December 8, 2017 with an exercise price of $0.36 and an original expiry of December 8, 2027 and (ii) 9,300,000 options granted on April 16, 2018 with an exercise price of $0.16 and an original expiry of April 16, 2023.  All of the cancelled options were voluntarily surrendered to the Corporation for no consideration.  In addition to the cancelled options, 8,850,000 options have expired as the holders thereof are no longer eligible participants under the Plan. Following the cancellations and expirations, the Corporation has a total of 43,150,803 stock options currently issued and outstanding under the Plan.

About Elixxer Ltd. (www.Elixxer.com)

Elixxer is a Canadian public company listed on the TSX Venture Exchange (TSX-V: ELXR) and the US OTC-QB exchange (OTCQB: ELIXF).

Through its partners, Elixxer presently has significant interests in Australia, Jamaica, Switzerland, Italy and Canada.

For further information please contact: 

Mazen Haddad, CEO: mazen@elixxer.com 

Caution Regarding Press Releases

Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Notice Regarding Forward Looking Statements

This press release may contain forward-looking statements with respect to Elixxer and its operations, strategy, investments, financial performance and condition. These statements can generally be identified by use of forward-looking words such as “may”, “will”, “expect”, “estimate”, “anticipate”, “intends”, “believe” or “continue” or the negative thereof or similar variations. The actual results and performance of Elixxer could differ materially from those expressed or implied by such statements. Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding future expectations. Some important factors that could cause actual results to differ materially from expectations include, among other things, general economic and market factors, competition, government regulation and the factors described under “Risk Factors and Risk Management” in Elixxer’s most recent Management’s Discussion and Analysis filed on SEDAR (www.sedar.com). The cautionary statements qualify all forward-looking statements attributable to Elixxer and persons acting on its behalf. Unless otherwise stated, all forward-looking statements speak only as of the date of this press release, and Elixxer has no obligation to update such statements, except to the extent required by applicable securities laws.